Abstract:Abstract Glioblastoma (GBM) is the most common and deadly adult brain cancer with a post-diagnosis survival of 8-15 months even with treatment, highlighting a desperate need for new therapeutic strategies. One promising strategy involves the use of chimeric antigen receptor T-cell (CAR-T) therapy, created by engineering patient T-cells to express a CAR that recognizes a tumor-specific surface antigen thus allowing for directed tumor cell killing. While CAR-T therapy has experienced unprecedented success in treating hematologic malignancies, its application in solid tumors has proven challenging. However, early clinical studies in GBM have shown promise including a case in which a patient with disseminated GBM experienced a complete response. Unfortunately, the patient relapsed highlighting both potential therapeutic efficacy and our limited knowledge of resistance and relapse mechanisms. Established resistance mechanisms include tumor target antigen loss or intrinsic CAR-T failure, but there are certainly others that have yet to be identified. Furthermore, solid tumors present unique challenges and may possess distinctive resistance mechanisms related to hostile, immunosuppressive tumor microenvironments and vast inter-tumoral heterogeneity. Ultimately, improved understanding could lead to increased therapeutic efficacy through CAR-T combination therapies or direct CAR-T cell modifications. Beyond the promise of CAR-T however, there still remains a scarcity of effective treatment options for GBM, underscoring a critical need to gain a better fundamental understanding in order to create additional novel therapeutic strategies. In order to both understand mechanisms of resistance to CAR-T therapy in GBM and uncover novel tumor dependencies for therapeutic exploitation, I took an unbiased, functional genomics approach. I conducted a series of in vivo genome-wide screens in an orthotopic, immunocompetent mouse model of GBM using a novel, modular, small-pooled CRISPR/Cas9 single guide (sgRNA) library. Cas9-expressing tumor cells with library sgRNAs were intracranially injected into mice that subsequently received no treatment or direct intertumoral injection of non-targeting control or targeting CAR-T cells. Top depletion and enrichment hits were used to generate 2 separate validation libraries one containing CAR-T sensitization or resistance hits and the other containing hits essential for in vivo tumor growth and therefore potentially exploitable as novel therapeutic targets. Validation libraries were screened in the same manner as the original genome-wide screen and top hits are actively being validated with planned in-depth mechanistic follow up. Importantly, to date, these are the first in vivo genome-wide CRISPR/Cas9 screens conducted in an orthotopic, immunocompetent mouse model of GBM. Ultimately, these results could aid not only in the identification of novel therapeutic strategies for GBM and potential improvements in CAR-T clinical efficacy, but also in a broader understanding of the fundamental biology that underlies treatment resistance in GBM. Citation Format: Catherine E. Koch, Charles A. Whittaker, Michael T. Hemann. In vivo genome-wide CRISPR/Cas9 screens conducted in an immunocompetent mouse model of glioblastoma identify novel in vivo tumor liabilities and potential mechanisms of resistance to chimeric antigen receptor T-cell (CAR-T) therapy [abstract]. In: Proceedings of the AACR Special Conference on Brain Cancer; 2023 Oct 19-22; Minneapolis, Minnesota. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_1):Abstract nr PR-003.

Engineered Extracellular Vesicle-Delivered CRISPR/Cas9 for Radiotherapy Sensitization of Glioblastoma

Kill two birds with one stone: Engineered exosome-mediated delivery of cholesterol modified YY1-siRNA enhances chemoradiotherapy sensitivity of glioblastoma

Abstract PR-003: In vivo genome-wide CRISPR/Cas9 screens conducted in an immunocompetent mouse model of glioblastoma identify novel in vivo tumor liabilities and potential mechanisms of resistance to chimeric antigen receptor T-cell (CAR-T) therapy

Radiation-Triggered Selenium-Engineered Mesoporous Silica Nanocapsules for RNAi Therapy in Radiotherapy-Resistant Glioblastoma

Low-Dose Precision Radiotherapy for Glioblastoma Multiforme Via Programmed Combination for Sensitized Radioenhancement

CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy

Upregulation of DNA Metabolism-Related Genes Contributes to Radioresistance of Glioblastoma.

Nanoradiosensitizers in glioblastoma treatment: recent advances and future perspectives

Unlocking Glioblastoma Vulnerabilities with CRISPR-Based Genetic Screening

Biomimetic Nanosensitizer Potentiates Efficient Glioblastoma Gene-Radiotherapy through Synergistic Hypoxia Mitigation and PLK1 Silencing

CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis/TMZ resistance in the mesenchymal subtype of glioblastoma

Blood-brain barrier–penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy

Dddr-42. Leveraging Genome-Wide Crispr/Cas9 Knockout Drug Screens To Identify Sensitizers For Proteosome Inhibitors In Glioblastoma

Universal theranostic CRISPR/Cas13a RNA-editing system for glioma

Simultaneous Modulation of Hypoxia And Metabolism in Glioblastoma for Enhanced Radio‐Immunotherapy

In vivo perturb-seq of cancer and microenvironment cells dissects oncologic drivers and radiotherapy responses in glioblastoma

Engineering Nanomedicine for Non-Viral RNA-Based Gene Therapy of Glioblastoma

Radiation-primed TGF-β trapping by engineered extracellular vesicles for targeted glioblastoma therapy

Targeting Nuclear Pore Complex to Radiosensitize Glioblastoma Stem Cells

Identification of genetic modifiers enhancing B7-H3-targeting CAR T cell therapy against glioblastoma through large-scale CRISPRi screening

Gelsolin knockdown confers radiosensitivity to glioblastoma cells